Correspondence patrik.verstreken@kuleuven.vib.be In Brief Valadas et al. show that ER lipid imbalance causes sleep pattern defects in Parkinson's disease by preventing the formation of secretory vesicles required for the release of the neuropeptides. Restoring the ER lipid balance by supplementation with phosphatidylserine rescues the cellular and behavioral defects.
INTRODUCTION
Parkinson's disease (PD) affects about 1% of the population older than 60 years (de Lau and Breteler, 2006) . Whereas motor symptoms and loss of dopaminergic neurons are hallmarks of the disease (Braak et al., 2003) , 99% of the patients report non-motor symptoms that include sleep defects, cognitive impairment, depression, olfactory loss, and constipation (Munhoz et al., 2015) . Many patients also suffer from type 2 diabetes mellitus (De Pablo-Ferná ndez et al., 2017) . Sleep pattern disturbances are particularly burdensome to Parkinson's disease patients (Politis et al., 2010) and manifest as insomnia, sleep fragmentation, rapid eye movement (REM) sleep behavior disorders, and loss of circadian rhythms (De Cock et al., 2008) . These highly prevalent symptoms occur very early in the disease, often years prior to dopaminergic neuron loss and motor symptoms (Lee and Koh, 2015) . Furthermore, dopaminergic replacement therapy in Parkinson's disease patients is able to significantly restore motor function but is insufficient to rescue the non-motor symptoms of the disease, including sleep pattern disturbances (Lee and Koh, 2015) . This suggests that sleep defects originate from dysfunction of a distinct circuitry. However, the origin of sleep defects in Parkinson's disease remains elusive.
Although Parkinson's disease animal models have been tested for sleep coordination defects, the characteristic defects in circadian rhythmicity, disruption of REM sleep and sleep fragmentation seen in patients, are rarely observed in animal models (Fifel et al., 2016) . This is probably because many Parkinson's disease models selectively target the dopaminergic system. Although mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, 6-hydroxydopamine (6OHDA), or deficient for vesicular monoamine transported (VMAT) show typical dopaminergic neuron degeneration (Fifel et al., 2016) , they do not present the diverse and frequent non-motor symptoms of the disease. In addition, animal models of familial Parkinson's disease, where specific genes are knocked out or pathogenic mutations are expressed, do not present the sleep phenotypes typical of the disease (Fifel et al., 2016) . Hence, models that broadly affect the nervous system are needed to study non-motor symptoms of Parkinson's disease. Whereas Parkinson's disease is primarily a sporadic disease, about 10% is familial (Lill and Klein, 2015) . Interestingly, both sporadic and familial Parkinson's disease patients display early-onset sleep defects, suggesting this is fundamental to the disease (De Cock et al., 2008; Kasten et al., 2010) . Among Parkinson's disease genes, parkin and pink1 are relatively well studied, and their protein products act in a common pathway to ubiquitinate mitochondrial target proteins, resulting in mitochondrial degradation (Dawson and Dawson, 2010; Valadas et al., 2015) . parkin encodes for the E3 ubiquitin ligase that catalyzes the ubiquitination of specific targets, guiding them to degradation or to a different cellular location (Pickrell and Youle, 2015) . If Parkin function is impaired, its targets accumulate in the cell. Pink1 is a kinase that activates Parkin by phosphorylation (Pickrell and Youle, 2015) . Upon mitochondrial depolarization, Pink1 is stabilized on the outer mitochondrial membrane and recruits Parkin to promote the removal of damaged mitochondria (Pickrell and Youle, 2015) . An expected long-term consequence of Parkin or Pink1 loss is the accumulation of dysfunctional mitochondria (Pickrell and Youle, 2015) ; however, this is not observed in all neuronal cell types in vivo. In addition to causative mutations in the parkin gene, Parkin protein is also often inactivated in sporadic Parkinson's disease (Dawson and Dawson, 2010) , and similar to sporadic Parkinson's disease, patients with parkin or pink1 mutations exhibit sleep pattern defects (Kasten et al., 2010) .
Parkin and Pink1 are broadly expressed in the brain (Stichel et al., 2000; Taymans et al., 2006) , and in this work, we use loss-of-function mutations in parkin and pink1 and study them both in hypothalamic neurons differentiated from patient induced pluripotent stem cells (iPSCs) and in fruit flies to dissect the molecular, cellular, and neurobiological origin of the circadian and sleep pattern defects in Parkinson's disease. We find that excess transfer of phosphatidylserine at the endoplasmic reticulum (ER)-mitochondrial contacts of mutant neuropeptidergic neurons causes a defect to produce loaded secretory vesicles that control circadian rhythms. Increasing phosphatidylserine levels is sufficient to rescue secretory vesicle production and sleep pattern defects in the Parkinson's disease models.
RESULTS

Parkinson's Disease Models Have Sleep Pattern Defects
The mechanisms of sleep maintenance and circadian rhythmicity control are well conserved across species, including Drosophila melanogaster (Hendricks and Sehgal, 2004; Hendricks et al., 2000) . Besides a higher threshold to arousal, sleeping flies do not move, and inactivity over a 5-min period is regarded as a good measure of sleep, also verified by alternative methodologies Hendricks et al., 2000) . To assess features of circadian rhythmicity, we used automated monitoring to continuously follow the movement of flies that lack parkin or pink1 (Park et al., 2006; Pesah et al., 2004) . Interestingly, several aspects of the circadian pattern are disrupted in both parkin and pink1 mutants compared to controls as summarized in Figures 1A and S1A-S1C.
Two sleep pattern features are particularly disrupted in pink1 and parkin mutants, and these defects are also observed in the disrupted sleep patterns of Parkinson's disease patients: (1) the anticipation of dawn and (2) the fragmentation of sleep (De Pablo-Ferná ndez et al., 2017; Peeraully et al., 2012) . Wild-type flies kept on a 12-hr dark-light cycle use their endogenous circadian rhythms to anticipate the timing of dusk or dawn, becoming more active in the 3-hr period preceding these events ( Figure 1A ; Chiu et al., 2010) . In contrast, flies with parkin or pink1 mutations fail to anticipate dawn (and to a lesser extend dusk) and remain inactive until the switch to light (Figures 1B and 1C) . We confirm that the morning and evening anticipation defects are specific to parkin or pink1 loss by analyzing different independently generated mutants ( Figure S1D ). In addition, the defects in morning and evening anticipation are also reversed by re-expressing wild-type Parkin or Pink1, but not by re-expressing mutant forms of these proteins ( Figures 1B, 1C , and S1D; Clark et al., 2006; Pesah et al., 2004) . Note that the presence of these genomic rescue constructs in a wild-type background does not affect any of the measured parameters. Furthermore, we also find that parkin and pink1 mutant flies show normal overall locomotor activity, ruling out that our observations are the result of decreased motor ability ( Figure S1E ).
To further examine this circadian defect in parkin and pink1 mutants, we trained the flies in 12 hr light-dark cycles for 7 days and then assessed the maintenance of circadian rhythmicity in the absence of a light cycle by keeping the flies in constant darkness. Despite the continuous darkness, wild-type flies still display a strong circadian-dependent oscillatory pattern with a bout of activity at dusk and dawn. In contrast, parkin and pink1 mutants have a weaker oscillatory amplitude (Figures S1F and S1G). The circadian period, which is a direct measurement of the coordinated expression and degradation of the circadian genes and proteins (period, clock, etc.) , is not altered in flies with parkin or pink1 mutations ( Figure 1D ); however, we detect a significant decrease in the number of rhythmic flies ( Figure 1E ) and a loss of the circadian power ( Figure 1F ). These results implicate Parkin and Pink1 in the control of endogenous circadian rhythmicity through a mechanism independent of the regulation of the circadian genes.
Another prominent feature observed in Parkinson's disease patients is an inability to maintain sleep, manifested as sleep fragmentation during the night (Peeraully et al., 2012) . As noted above, we find frequent awakenings (short periods of activity that are preceded and succeeded by a sleep period) in parkin and pink1 mutant flies, and these occur both during the night and day ( Figures 1G, 1I , 1J, and S2A-S2D). Again, we rescue these defects by re-expressing wild-type Parkin or Pink1 (Figures 1G , 1I, 1J, and S2A-S2D). The sleep fragmentation is the result of a decrease in the length of the sleep bouts and an increase in their frequency ( Figures S2E-S2H ). Whereas parkin and pink1 mutant flies display fragmented sleep, similar to patients, their total amount of sleeping minutes (at night or during the day) is not affected (Figures 2A and 2B ). Indicating specificity, we find very similar results by expressing two independently generated parkin and pink1 RNAi lines ( Figure S2N ). Our observations are in line with models of how these neurons regulate the circadian cycle (LNvs; Helfrich-Fö rster and , and the power of the circadian cycle (F) of controls, parkin, and pink1 mutants (without and with a genomic rescue construct) entrained in a 12-hr light-12-hr dark cycle and tested in constant dark conditions. In (D) and (F), only rhythmic flies were quantified. n = 20-23 flies. ns, not significant; ***p < 0.001 by Bonferroni's test following one-way ANOVA. Data are represented as mean ± SEM. (G-J) Quantification of the number of brief awakenings in a 24-hr period (G) and the number of sleeping minutes in a 24-hr period (H) for control flies, parkin, and pink1 mutants (with or without a genomic rescue construct) and 24-hr activity plots of individual flies (rows; I and J). Each vertical bar represents an active minute. n = 5-9 assays with more than 25 flies per assay. ns, not significant, **p < 0.01 and ***p < 0.001 by Bonferroni's test following one-way ANOVA. Data are represented as mean ± SEM. See also Figures S1 and S2. Homberg, 1993; Renn et al., 1999) or sleep maintenance (IPCs; Crocker et al., 2010) . Indeed, we confirm that genetic ablation of the neurons using upstream activating sequence (UAS)-hid or UAS-ricin also results in decreased morning anticipation (ablation of LNvs) and increased brief awakenings (ablation of IPCs; Figures S2O and S2P ). Hence, loss of Parkin or Pink1 function in specific neuropeptidergic neurons is sufficient to recapitulate aspects of the circadian and sleep pattern defects. To determine whether Parkin or Pink1 function in the LNvs alone is sufficient to support normal morning anticipation, we removed Parkin or Pink1 function everywhere except in LNvs. We used tubulin-Gal4 to express RNAi in all cells but inhibited Gal4 activity in LNvs by expressing Gal80 (PDF-Gal80; Figure 2C ; Stoleru et al., 2004) . parkin RNAi -or pink1 RNAi -expressing flies (using tubulin-Gal4) show a defect in morning anticipation and increased brief awakenings ( Figure 2D ), but in the presence of PDF-Gal80, the morning anticipation defect is rescued (Figure 2D ). As expected, the increased brief awakenings persist in the presence of PDF-Gal80, again indicating that this defect is elicited by the loss of Parkin or Pink1 in other cells than the LNvs (e.g., IPCs; Figure 2E ). These results also imply that Pink1 and Parkin elicit morning anticipation defects independent of dopaminergic neuron dysfunction. We confirm this by expression of parkin RNAi or pink1 RNAi using the dopaminergic driver pleGal4 and find it does not affect the morning anticipation score (Figures 2A and 2B) . This indicates morning anticipation is independent of Pink1 and Parkin function in dopaminergic cells. Conversely, we do observe a defect in brief awakenings upon parkin RNAi expression (but not upon pink1 RNAi expression) using ple-Gal4 (Figures 2A and 2B ). This is consistent with the idea that, in addition to its role in IPCs, Parkin function in dopaminergic circuits may regulate this phenotype. Nonetheless, our results indicate that Pink1 and Parkin are required in specific neuropeptidergic neurons to control circadian rhythms and sleep patterns.
Neuropeptides Are Arrested in Neuronal Cell Bodies of parkin and pink1 Mutant Flies and Patient-Induced Neurons
We first looked at LNvs in more detail because knockdown of Parkin or Pink1 in these neurons causes strong phenotypes in morning anticipation score. In addition, prior studies indicated that Parkin RNA levels in LNvs are enriched 12-fold over other neurons in the fly brain (Kula-Eversole et al., 2010) . Finally, Parkin and Pink1 mRNA levels oscillate with the circadian cycle, being higher at night (Kula-Eversole et al., 2010) , when the LNvs actively release PDF. We therefore assessed whether parkin and pink1 mutant LNvs produce PDF-loaded vesicles and transport these to the terminals. We labeled mutant brains at zeitgeber time 23 (1 hr before the lights-on event) with anti-PDF antibody ( Figure 3A ). This finds reduced levels of PDF at neuron terminals and increased PDF levels in cell bodies compared to controls ( Figures 3B and 3C ). These differences are not because of changes in PDF mRNA expression levels in the mutants as gauged by qPCR ( Figure S3A ). Furthermore, the PDF distribution defects are recapitulated by Note that RNAi expression with PDF-Gal4 recapitulates the morning anticipation defect whereas several other neuronal drivers, including the Ilp2-Gal4, recapitulate the brief awakening defect (n = 3-8 assays with more than 25 flies per assay).
(C) LNv-specific requirements for Parkin and Pink1 function to elicit morning anticipation defects. Graphic representation of where Gal4 is present to drive RNAi expression. PDF-Gal4 expresses RNAi only in LNvs, and tubulin-Gal4 broadly expresses RNAi. In the presence of tubulin-Gal4, PDF-Gal80 neutralizes Gal4 activity in LNvs, whereas Gal4 is still active in the remaining neurons. RNAi-mediated downregulation of Parkin or Pink1 in LNvs, indicating the effect is cell autonomous to these neuropeptidergic neurons ( Figures S3B-S3E ). Next, we analyzed the defects underlying the brief awakenings phenotype that was strongly affected in pink1 and parkin mutants. Loss of Pink1 and Parkin in several neuropeptidergic neuron clusters and the loss of Parkin in the dopaminergic neurons affected this parameter (Figures 2A and 2B ). We chose to analyze neuropeptide distribution in the IPCs because of their concentrated, specific localization in the brain ( Figure 3A' ) and because we have access to specific antibodies that recognize drosophila Insulin-like peptide type 2 (dIlp2), produced in the IPCs (Rulifson et al., 2002) . We find dIlp2 labeling is increased in the IPC cell bodies and decreased in the IPC neuron terminals ( Figures 2D and 2E) . Hence, both dIlp2 (in the IPCs) and PDF (in the LNvs) fail to properly localize at terminals and are retained in the cell body. To further test the neuropeptide distribution defects, we expressed an exogenous neuropeptide, rat neuropeptide atrial natriuretic factor tagged with GFP (ANF-GFP) (Rao et al., 2001) in the LNvs or IPCs. ANF uses the fly cellular machinery to be produced and processed, and we find it is also retained in the cell bodies of the LNvs ( Figure S3F ) and of the IPCs ( Figure S3G ) of parkin mutant flies. Finally, the defect we observe is specific to neuropeptides because expression of synaptotagmin-GFP, a synaptic-vesicle-associated protein also produced in the cell body, distributes normally to synapses of LNvs in the mutants (Figures S3H and S3I) . These data indicate that neuropeptide distribution is broadly affected in Parkinson's disease mutant flies.
Fly LNvs are analogous to neurons in the human hypothalamus, and both fly and human neurons secrete neuropeptides in the hours preceding dawn (Kunst et al., 2015; Richter et al., 2014) . Human neurons secrete vasoactive intestinal peptide (VIP), whereas fly neurons secrete the VIP-like neuropeptide PDF (Vosko et al., 2007) . To determine whether our findings are evolutionary conserved, we generated induced human hypothalamic neurons ( Figure S4A ; Merkle et al., 2015) . We used two patient-derived iPSCs carrying parkin mutations, two patients with pink1 mutations, and two age-matched individuals without Parkinson's disease ( Figure S4B ; Seibler et al., 2011; Zanon et al., 2017) . We confirmed that these four patients suffered from sleep disturbances, whereas the control individuals had no complaints ( Figure S4B ). Differentiated hypothalamic neurons with or without parkin and pink1 mutations express mature neuronal markers and neuropeptides, including VIP, a circadian coordinator in mammals ( Figures 4A and S4C ). Similar to the observations in flies, we find that anti-VIP immunoreactivity is lower in neurites and increased in cell bodies of the neurons derived from the four patients ( Figures 4B and 4C) . Consistently, ELISAbased measurements of extracellular VIP show that the induced hypothalamic neurons from these patients also secrete less VIP into the medium than control cells when the neurons are chemically stimulated ( Figure 4D ). Hence, VIP delivery to synapses in parkin or pink1 mutant human neurons is impaired, also causing a defect in the coordinated release of this neuropeptide.
Neuropeptides Are Arrested in the ER of Parkinson's Disease Mutant Neuropeptidergic Cells Neuropeptides are produced in the ER and then transported through the Golgi network and loaded in dense core vesicles (DCVs) that are finally transported to the release sites. The increased labeling of neuropeptides in the cell body of parkin or pink1 mutant neurons can be explained either by a defect in trafficking of DCVs to their release sites, resulting in the accumulation of DCVs in cell bodies or by the retention of neuropeptides in the ER-Golgi complex, e.g., as a result of a defect to produce DCVs.
To analyze DCV number and location in LNvs in the brain, we used correlative 3D Block face scanning electron microscopy. We labeled LNvs with anti-PDF antibody coupled to horseradish peroxidase (HRP) that converts diaminobenzidine (DAB) into a precipitate visible by electron microscopy (EM) (Figures S5A-S5D ). Cell bodies of LNvs were then reconstructed, and DCVs were identified based on morphology. The number of DCVs is significantly lower in cell bodies of parkin mutants (Figures 5A and S5E) . Hence, despite the increased levels of PDF in parkin mutant LNv cell bodies, we find less DCVs. These data are consistent with a requirement for Parkin in the production of DCVs.
Neuropeptide packaging and trafficking is coupled to their post-translational processing while they transfer from the ER to the Golgi into DCVs (Loh, 1987) . To directly assess neuropeptide processing, we expressed dIlp2-GFP in the IPC neurons and performed western blotting to detect immature and mature forms of dIlp2 (the GFP moiety facilitates detection on western blotting). dIlp2-GFP is produced as an immature pre-pro-neuropeptide in the ER and is then consecutively cleaved by the fly machinery to the fully processed form that resides in DCVs (Arvan and Castle, 1998; Brogiolo et al., 2001) . Consistent with our observation of decreased DCV number parkin mutants, we find a significant accumulation of immature uncleaved dIlp2-GFP (approximately [approx.] 42 kDa) and a decrease in the partially (approx. 39 kDa) and fully processed dIlp2-GFP (approx. 31 kDa; Figures 5C and 5D ). We independently confirm this result by expressing ANF-GFP in parkin mutants, where we also observe an increased amount of unprocessed and partially processed ANF-GFP at the expense of the fully processed form (Figures S5F and S5G; Rao et al., 2001) . These data are consistent with reduced DCV formation in parkin mutants.
Increased ER-Mitochondrial Contacts in parkin and pink1 Mutant Neuropeptidergic Neurons We next wondered how the function of Parkin and Pink1 could connect to DCV formation. Pink1 recruits Parkin to mitochondria, where it ubiquitinates proteins (Geisler et al., 2010) . In some cell types, the loss of parkin or pink1 results in morphologically abnormal mitochondria (Esposito et al., 2013; Pesah et al., 2004) . However, in many other cell types, including several types of neurons in flies, mice, and patients, chronic loss of parkin and pink1 does not cause overt mitochondrial morphological defects (Burman et al., 2012; Clark et al., 2006; Damiano et al., 2014; Gautier et al., 2008; Morais et al., 2009; Pickrell and Youle, 2015) . We therefore labeled mitochondria by expressing mito-GFP in LNvs or with an antibody targeting TOM20 in human hypothalamic neurons with parkin or pink1 mutations. This did not reveal significant changes in mitochondrial volume or mitochondrial morphology between the mutant cells and control cells (Figures S5H-S5J ). We also assessed mitochondrial morphology in LNvs using electron microscopy. This does not reveal obvious abnormalities in cristae structure in the LNvs of parkin mutants ( Figure S5K) .
Proteins ubiquitinated by Parkin are typically sent for degradation, and an inability to ubiquitinate them leads to elevated levels of these Parkin targets both in parkin and pink1 mutants. This has been observed for mitofusin (Drosophila MARF), VDAC (Drosophila porin), and Miro (Geisler et al., 2010; Poole et al., 2010; Wang et al., 2011) . Interestingly, several of these targets are proteins that stabilize ER-mitochondrial contact sites (Figure S6A; de Brito and Scorrano, 2008; Erpapazoglou and Corti, 2015; Helle et al., 2013; Poston et al., 2013) . Consistently, the loss of parkin has been shown to result in more ER-mitochondrial contacts (Celardo et al., 2016; Gautier et al., 2016) , but this was not tested in LNvs in vivo. We imaged fluorescently labeled ER and mitochondria in LNv and IPC cell bodies to evaluate the distance distribution between these organelles (see STAR Methods). This analysis indeed finds a significant increase in the contact surface between these organelles in LNvs and IPCs of parkin and pink1 mutants ( Figures 6A-6D , S6B, and S6C). Similarly, we also find an increase in the ER-mitochondrial contact surface when we overexpress the Parkin target MARF in LNvs, indicating that the upregulation of Parkin targets is sufficient to generate more contacts ( Figure S6D ). We independently confirm the contact surface is increased based on volume reconstructions of our 3D EM data stacks of parkin mutant LNv cell bodies, where we highlight areas where ER and mitochondria are within a distance of <30 nm in yellow ( Figure 6E ). These data indicate that the loss of Parkin activity promotes the formation of ER-mitochondrial contacts in fly LNvs.
To determine whether the increased ER-mitochondrial contact surface is evolutionary conserved, we resorted to our induced hypothalamic neurons differentiated from patient iPSCs. We used antibodies to label ER (anti-protein disulfide-isomerase [PDI] ) and mitochondria (anti-TOM20) and also find an increased contact surface between ER and mitochondria in mutant neurons ( Figures 6F, 6G , and S6E). Hence, both in mutant fly LNvs and IPCs, as well as in induced neuropeptidergic neurons from Parkinson's disease patients, the contact surface between ER and mitochondria is increased.
Increased ER-Mitochondrial Contacts Cause Morning Anticipation Defects in Drosophila
Our data suggest that defects to produce PDF-loaded DCVs in the ER-Golgi system cause circadian defects. We therefore Quantification of the extent of the contacts between ER and mitochondria in LNv (B) and IPC (D) cell bodies of parkin and pink1 mutants (e.g., quantification of the frequency of ER pixels within a distance of one pixel from mitochondria). n = 7-9 brains for (B) and 16-24 brains for (C) per condition. *p < 0.05 and ***p < 0.001 by Bonferroni's test following one-way ANOVA. Data are represented as mean ± SEM. (E) 3D model of an LNv cell body generated from a FIB-SEM data stack of a control and a parkin mutant fly indicating ER (green), mitochondria (red), and the contacts between them (locations where the organelles are <30 nm apart, yellow). Nucleus, blue; cytoplasm, gray; box, inset. (F and G) Images of induced hypothalamic neurons of controls, parkin, and pink1 mutant patients (F, left) labeled with anti-PDI (ER, green) and anti-TOM20 (mitochondria, red) and the outline of ER and mitochondria labeling, where arrowheads indicate where the labeling connects (F, right). Quantification (G) of the extent of the contacts between ER and mitochondria in control, parkin, and pink1 mutant hypothalamic differentiated neurons. n = 16-20 neurons per genotype from two independent differentiations. *p < 0.05 and **p < 0.01 by Bonferroni's test following one-way ANOVA. Data are represented as mean ± SEM. See also Figure S6 . (B and C) Images of LNv neuronal terminals and cell bodies of animals overexpressing MARF or porin in LNv (PDF-Gal4) and labeled with anti-PDF (B) or also expressing ANF-GFP, where GFP was imaged (C). Note the increased neuropeptide labeling in the cell bodies and reduced labeling at terminals. Quantification is shown in Figures S7A-S7D . (D) Quantification of morning anticipation upon downregulation of MARF in LNv (PDF-Gal4) of parkin and pink1 mutants. Note that this rescues the defects of parkin and pink1 mutants. n = 4-6 assays with 25 flies each. ns, not significant, *p < 0.05, **p < 0.01, and ***p < 0.001 by Bonferroni's test following one-way ANOVA. Data are represented as mean ± SEM. (E and F) Images of LNv neuronal terminals and cell bodies upon downregulation of MARF in LNv (PDF-Gal4) of parkin (E) and pink1 (F) mutants, labeled with anti-PDF. Note that this rescues the defects of parkin and pink1 mutants. Quantification is shown in Figures S7E-S7H. (G) ChiMERA bridges the mitochondrial and ER membrane to induce additional contacts between these organelles.
(legend continued on next page) determined whether the increased ER-mitochondria contacts we observe in parkin and pink1 mutants are causal to morning anticipation defects. We started by overexpressing MARF (or porin) in LNvs of wild-type flies where ER-mitochondrial contacts are increased ( Figure S6D ). This causes PDF retention in cell bodies and decreases morning anticipation, very similar to our observations in parkin or pink1 mutants ( Figures 7A, 7B, S7A , and S7B). Similarly, when we express ANF-GFP that marks DCVs and colocalizes with PDF ( Figure S7J ) in the flies that overexpress MARF or porin, the ANF-GFP accumulates in LNv cell bodes at the expense of localizing to terminals ( Figures 7C,  S7C, and S7D) . Conversely, we knocked down the Parkin target MARF ( Figure S7I ) in parkin or pink1 mutants and find this partially rescues the PDF accumulation in the cell body as well as the defect in morning anticipation ( Figures 7D-7F and S7E-S7H). Our attempts to also test another target (porin) failed, as we were unable to generate the flies. These genetic interactions are consistent with increased ER-mitochondrial contacts to cause the circadian defects we observed in parkin and pink1 mutants.
To provide further evidence for a specific role of ER-mitochondrial contact sites in the regulation of morning anticipation, we created transgenic flies that express ''ChiMERA,'' where ERmitochondrial contacts are upregulated without the confounding factors that may arise from overexpression of endogenous proteins, such as MARF or porin. The ChiMERA protein consists of the yeast TOM70 mitochondrial membrane protein fused to the yeast ER protein, Ubc6, and GFP (Figures 7G, S7K, and S7L; Kornmann et al., 2009 ). Similar to the overexpression of MARF or porin, this tool drives ER-mitochondrial contact formation (Kornmann et al., 2009) . Interestingly, expression of ChiMERA in LNvs causes a decrease in morning anticipation ( Figure 7H ). Furthermore, expression of ChiMERA results in the increased retention of PDF in LNv cell bodies and in lower levels of this neuropeptide in the LNv terminals ( Figures 7I,  S7M, and S7N) . Hence, ER-mitochondrial contacts drive circadian rhythm defects similar to those observed in Parkinson's disease models.
Excessive Phosphatidylserine Transfer at ERMitochondrial Contacts Cause Circadian Rhythm and Sleep Pattern Phenotypes in parkin and pink1 Mutants ER-mitochondrial contacts are involved in different cellular processes, such as Ca 2+ export from ER to mitochondria, generation of autophagic membranes, facilitation of the ER stress response, regulation of apoptosis, and also the transport of phosphatidylserine (PtdSer) from the ER to mitochondria, where it is metabolized to phosphatidylethanolamine (PtdEtn) (Figure S8A ; Area-Gomez, 2014; Paillusson et al., 2016) . Whereas we did not find evidence for a role of ER-calcium and stress in the generation of DCVs in the literature, PtdSer has been reported to be enriched in DCV membranes (Kim et al., 2014; Westhead, 1987) . Based on this, we hypothesized that the increased ER-mitochondrial contact sites in the Parkinson's disease mutants affect DCV production via effects on lipid membrane composition, without excluding potential other ER-related processes that may be at play as well.
To examine the lipidome of ER-Golgi-and mitochondria-enriched membranes purified from parkin mutants and controls, we used shotgun lipidomics. Our mitochondria-enriched fraction presents high levels of the mitochondria-resident protein ATP synthase, whereas the ER-Golgi-enriched fraction has high levels of calreticulin, a protein in the ER lumen ( Figures S8B  and S8C ). Both fractions only have residual levels of Discs large (DLG), a postsynaptic marker ( Figure S8C ), indicating that our fractions are relatively pure. The protein-to-lipid ratio and the mitochondrial and ER-Golgi concentrations of phosphatidylcholine (PtdCho) are similar in controls and mutants ( Figures 8A and  S8D) . However, the mitochondrial fraction of parkin mutants contains significantly more PtdSer and PtdEtn than the mitochondrial fraction of controls, whereas the ER fraction of parkin mutants contains comparatively less PtdSer and PtdEtn than the ER fraction of controls ( Figure 8A ). This is in accordance with the increased ER-mitochondria contacts that facilitate the transfer of PtdSer from ER to mitochondria in parkin mutants. Mitochondrial enzymes then convert PtdSer to PtdEtn, and this creates a ''PtdSer sink.''
We independently confirmed the importance of ER-mitochondrial contacts to deplete PtdSer from ER by expressing ChiMERA in otherwise wild-type flies. This manipulation is sufficient to drive a similar lipid profile to the one we detect in parkin mutants ( Figure 8A ), further indicating that an increase in ERmitochondrial contacts is sufficient to cause the lipid distribution defects in parkin mutants. Thus, the data indicate that increased ER-mitochondrial contacts in parkin mutants or in ChiMERA-expressing flies mediate excess PtdSer transfer to mitochondria and the relative depletion of PtdSer from the ER.
Next, we tested whether PtdSer levels can affect circadian rhythms. We knocked down the ER-resident enzyme PtdSer synthase with RNAi in LNvs ( Figure S8E ) and find that this manipulation causes a retention of PDF in the LNv cell bodies and a reduction of this neuropeptide at the terminals ( Figures 8B,  S8F , and S8G). Furthermore, knocking down PtdSer synthase also is sufficient to cause a defect in morning anticipation (Figure 8C ) that is similar to that in parkin mutants. These data provide further evidence that a decrease in PtdSer levels in the ER-Golgi of parkin mutants can explain the phenotype we observe.
To test our model further, we also performed a rescue experiment and supplemented fly food with PtdSer. After three days of continued PtdSer feeding, the circadian and sleep defects of parkin and pink1 mutants improved: both morning anticipation ( Figure 8D ) and brief awakenings ( Figure S8H) . Furthermore, after 4 days of PtdSer feeding, the altered distribution of PDF and (H) Quantification of morning anticipation upon ChiMERA overexpression in LNv (PDF-Gal4). Note this phenocopies pink1 and parkin mutants. n = 5-8 assays with 25 flies each. *p < 0.05 by Mann-Whitney test. Data are represented as mean ± SEM. (I) Images of LNv neuronal terminals and cell bodies upon overexpression of ChiMERA in LNv (PDF-Gal4) labeled with anti-PDF. Note the increased neuropeptide labeling in the cell bodies and reduced labeling at terminals. Quantification is shown in Figures S7M and S7N . See also Figure S7 .
ANF-GFP in the LNvs of these parkin mutants is indistinguishable from the distribution we observe in controls fed or not fed with PtdSer ( Figures 7E, 7F , and S8I-S8L). Similarly, dIlp2 distribution in the IPC neurons of parkin mutants fed with PtdSer is also rescued to control levels ( Figures S8M and S8N) . As a control, we also fed parkin and pink1 mutants with PtdCho. However, here, we do not observe a rescue of brief awakenings or morning anticipation defects ( Figures S8O and S8P ). This result indicates PtdSer depletion specifically is the basis of the circadian and sleep pattern defects in parkin and pink1 mutants.
DISCUSSION
Our data provide neurobiological, cellular, and molecular explanations for circadian and sleep pattern impairments in Parkinson's disease-a clinically well-recognized but mechanistically Data for the first two days of feeding (days 1 and 2) were pooled, and data for the consecutive two days of feeding (days 3 and 4) were pooled. Note that, after 3 or 4 days of feeding, the morning anticipation defect is partially rescued, as is the defect in brief awakenings (shown in Figure S8H ). Longer periods of feeding do not yield stronger rescue of the morning anticipation phenotype (not shown). n = 7 assays with 25 flies each. *p < 0.05, **p < 0.01, and ***p < 0.001 by Tukey's test following two-way ANOVA. (E and F) Images of LNv neuronal terminals and cell bodies upon feeding control and parkin mutant flies PtdSer 150 mM (final concentration in the food) for 4 days, labeled with anti-PDF (E), or expressing ANF-GFP, where GFP was imaged (F). Quantification is shown in Figures S8I-S8L . Note the rescue of neuropeptide distribution upon PtdSer feeding. Similarly, PtdSer feeding also rescues dIlp2-GFP distribution defects in the IPCs (see Figures S8M and S8N ). See also Figure S8 . not understood phenomena. The data here show that the wellknown mitochondrial Parkinson's disease pathology in some of the genetic forms of the disease bifurcates in the cell at the level of the ER-mitochondrial contacts to affect other organelles like DCVs. These ER-mitochondrial contacts are central in aspects of lipid metabolism, and we find here that the lack of PtdSer, for not yet fully clarified reasons, affects the maturation of dense core vesicles in induced neurons from patients and in fly mutants.
It is a conundrum why the manifestation of phenotypes in neurodegenerative diseases caused by mutations in a single gene does not follow simply the level of the affected protein expression, i.e., not all cells respond in the same way to the presence of a mutated protein. Our data here suggest that understanding the basic cell biology is key: proteins express their function in the context of cells. We find that parkin and pink1 mutations in a set of neuropeptidergic neurons affect the boost of VIP secretion that needs to happen in the hours preceding dawn and possibly other peptides important for sleep pattern regulation as well. In fact, our mini-screen showed that knockdown of Parkin or Pink1 in other neuronal clusters also elicited sleep pattern phenotypes, sometimes even in opposite directions (e.g., DH31, Tdc2, or c316), but further work will be needed to elucidate their roles in the regulation of this process. Nonetheless, our data are consistent with the normal, basal DCV production to occur normally in these cells, but the massive and fast upregulation of DCV production that is required in a limited time window (at night) is impaired. It is clear that the particular function of these neurons makes them vulnerable to a, at first glance relatively mild, deficit in lipid metabolism that affects DCV formation. It is likely that this stabilization of ER-mitochondrial contacts may have different consequences for other cell types, and further work is needed to evaluate to what extent this alteration might activate other pathogenic stress pathways.
Sleep pattern and circadian defects and other non-motor symptoms of Parkinson's disease are relatively understudied compared to the dopaminergic neuron loss and concomitant motoric defects (Munhoz et al., 2015) . Part of the reason may be that murine models of familial and sporadic Parkinson's disease do not recapitulate the sleep pattern defects seen in patients (Fifel et al., 2016) . We also tested pink1 mutant mice using 24-hr activity monitoring but failed to detect consistent defects. We resorted to fruit flies that do recapitulate cardinal features of sleep pattern and circadian disturbances of Parkinson's disease. We believe this is warranted because we were able to recapitulate all the cellular defects seen in fly neuropeptidergic neurons and also in induced hypothalamic neurons from different patients that we show also display sleep defects. Moreover, the cellular and molecular substrates that regulate circadian rhythmicity and the mechanisms of sleep are evolutionary wellconserved, and several aspects were originally discovered in flies (Hendricks and Sehgal, 2004) .
A growing number of pathologies feature excess ER-mitochondrial contacts, for instance, familial Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and type 2 diabetes mellitus (Krols et al., 2016) . Interestingly, as in Parkinson's disease, also AD, ALS, and HD have marked and penetrant sleep pattern and circadian rhythmicity symptoms (Ahmed et al., 2016; Morton, 2013; Peter-Derex et al., 2015) . However, little is known about the defective cellular and molecular mechanisms at the basis of these sleep pattern defects in these different neurodegenerative diseases. Our study now provides a new direction that can be tested in the context of those diseases as well, by evaluating the processing and release of sleep-pattern-controlling neuropeptides. In this context, our findings are exciting, because it is known that ER-mitochondrial contacts in other cell types than neuropeptidergic neurons can adapt quickly to the needs of the cell (Prudent et al., 2015) . Our work suggests that, through its ubiquitination activity, Parkin can ''quickly'' regulate the prevalence of these sites in neuropeptidergic neurons as well, as to support the boost in DCV production needed at the hours preceding dawn.
Our findings have important clinical implications. Most importantly, the circadian and sleep pattern defects in Parkinson's disease are apparently caused-at least in part-by a different pharmacology than dopaminergic dysfunction, which underlies the well-known motoric dysfunction. Indeed, sleep dysfunction in Parkinson's disease is not rescued by dopamine replacement therapy (Lee and Koh, 2015) . In addition, our genetic work is in further support of this, as we show that, when parkin or pink1 are knocked down everywhere (also in the dopaminergic neurons), except in the LNvs, such animals do not show a defect in morning anticipation. It is also important to note that the disordered circadian rhythmicity and sleep patterns are caused by neuronal dysfunction and not neurodegeneration, which implies that it can be corrected, as we show here in flies by the addition of PtdSer to the food.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to the Lead Contact Patrik Verstreken (patrik. verstreken@kuleuven.vib.be). Human IPSC were used in accordance with an MTA with the University of L€ ubeck.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Fly stocks and maintenance Drosophila melanogaster fly stocks were handled using standard protocols, kept in a 12 hr light/dark cycle and fed a standard Drosophila diet consisting of cornmeal, agar, yeast, sucrose, and dextrose. All experimental crosses were kept at 25 C. Mutant and transgenic stocks were obtained from the Bloomington Drosophila Stock Center (BDSC), Kyoto Stock Center (DGRC), the Vienna Drosophila RNAi stock center (VDRC) or were gifts (see Key Resources B9 is a null mutant of pink1. Rescue flies express a genomic fragment containing parkin or pink1 (Clark et al., 2006; Pesah et al., 2004) . Rescue STOP flies express a genomic fragment containing parkin but with a premature STOP codon, preventing Parkin expression (Pesah et al., 2004) . w 1118 was used as control for parkin and pink1 mutants. Flies expressing an RNAi against luciferase (BDSC 31603) were used as control for all TRIP RNAi lines and flies with an empty landing site (VDRC 60100) were used as control for the KK RNAi lines. The UAS-ChiMERA construct (Kornmann et al., 2009 ) was generated using standard cloning procedures (using EcoRI and XhoI to integrate the ChiMERA in a pUAS vector). After confirming the sequence of the plasmid, germline transformation was achieved by injection of embryos at BestGene (USA) using the VK00037 landing site.
iPSC maintenance and differentiation iPSC from 2 parkin patients with gene deletions and point mutations (lines L3048, male; and L5415, female), 2 PINK1 patients with a premature STOP codon (lines L2124 and L2126, both females) as well as 2 matched controls (lines L4993 and L5991, both females, Figure S4B , Seibler et al., 2011; Zanon et al., 2017) were differentiated into hypothalamic neurons according to a protocol described before (Merkle et al., 2015) . Briefly, cells were maintained in matrigel coated plates with mTeSR1 (Stem Cell Technologies) and medium changes were performed every two days. For hypothalamic neuron differentiation, the supplements and media used are described in Figure S4A . After 14 days, cells were trypsinized and replated with maturation medium. At day 30, coverslips with differentiated neurons were placed over cultured rat glia for 10 days and then prepared for immunolabeling or neuropeptide release experiments.
METHOD DETAILS
Fly activity assay Male flies were selected from each group to be analyzed in the Drosophila Activity Monitor (DAM, from Trikinetics) in a 25 C incubator. 2-to 5-day-old male flies are individually introduced in DAM glass tubes . After 24 hr of habituation, fly activity was recorded for at least 3 consecutive days. The number of assays is indicated in the figure legends. Morning anticipation is defined as the ratio between the increase of the transitions in 3 hr that precede the light change (transitions 3/0 subtracted the basal activity, transitions 6/3 ) to the transitions on the 6 hr preceding the lights-on event (transitions 3/0 + transitions 6/3 ). The morning anticipation score of animals that do not increase their activity in the 3 hr before the lights-on event is represented as zero, while the score for animals that increase their activity in the last 3 hr of the dark period is a positive value.
morning anticipationð%Þ = transitions 3/0 À transitions 6/3 transitions 3/0 + transitions 6/3 3 100:
Lipid supplemented food experiment Food supplemented with 150 mM PtdSer or 300 mM PtdCho (1500x the amount of these lipids in the fly food (Carvalho et al., 2012) ) was prepared from the lipid stock in chloroform (25 mg/mL). The same volume of Chloroform was added in the control experiment. 1-to 3-day-old flies were used at the beginning of each experiment.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 7.0 software. The criteria for significance is: ns (not significant) p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Significant differences between 2 groups were analyzed using a two-tailed Mann-Whitney test. For more than 2 groups, a one-way ANOVA (with Bonferroni's post hoc correction for multiple comparisons) was used. For the lipid supplementation analysis, a two-way ANOVA (with Tukey post hoc correction for multiple comparisons) was used. The graph representation and error bars are defined in each legend, together with the definition of n and which statistical test was performed. Error bars show standard error of the mean (SEM), as indicated in the figure legend. Sample size was chosen according to that used for similar experiments in the literature.
